Duan, Jianchun <br/><br/>
Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysis.  [electronic resource] 

 -  JAMA oncology  03 2020 
 - 375-384 p.  digital 
<br/><br/> Publication Type: Journal Article; Meta-Analysis; Systematic Review 
<br/><br/><label>ISSN: </label>2374-2445 
<br/><br/><label>Standard No.: </label>10.1001/jamaoncol.2019.5367  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Agents, Immunological--therapeutic use<br/>B7-H1 Antigen--antagonists & inhibitors<br/>Humans<br/>Immune Checkpoint Inhibitors--therapeutic use<br/>Immunotherapy<br/>Neoplasms--drug therapy<br/>Programmed Cell Death 1 Receptor--antagonists & inhibitors<br/>Randomized Controlled Trials as Topic